Vaccination

The trial was called off because of futility of the toxoid vaccine candidate.

Approximately 11.7% of nearly 90,000 hospitalized patients with confirmed influenza suffered from an acute cardiovascular event.

A famed virologist weighs in on the country's earliest shortcomings—and how they can still be resolved today.

The vaccine induced T cell response in about 2 weeks, and antibody response in about 4 weeks, among 1000-plus healthy adults.

Why the virus is burdening US populations similar to other diseases.

Older patients with no stroke history are shown to have reduced risk for both shingles and stroke in new CDC data.

Seqirus announced approval of influenza A monovalent vaccine, adjuvanted (Audenz™) for protection against influenza A in a release on Monday morning.

New data for the 2019-2020 season shows the virus is at a high activity, but disease severity is moderate.

Though vaccination rates are decreasing in children and adolescents overall, it is not due to consideration of previous season's successes or failures.

Fewer than 2% of all patients hospitalized with pneumonia in 2014 received the vaccination.

Xofluza is currently being evaluated in a phase 3 development program for the reduced transmission of flu from an infected person to healthy people.

The CDC Influenza Division medical director reported new findings at IDWeek showing older patients with influenza subtype A were more likely to be hospitalized.

New findings presented at IDWeek show vaccinated children have inconsistent protection from the A(H3N2) flu subtype.

How a community-based assessment can show physicians the ways in which the flu spreads.

The CDC Influenza Division medical officer discusses findings from their pediatric assessment at IDWeek.

The vaccine is approved for use in high-risk individuals, and will be includied in the US Strategic National Stockpile.

A pair of phase 3 trials show the single-dose oral drug could have expanded benefits for influenza, just months before an sNDA ruling.

CDC data show the infectious respiratory disease has been on a decline since at least 2007—though measures are still needed to address its prevalence in certain populations.

The current vaccine strategy is effective, but lacks a streamlined approach.

A look into the reasoning behind the vaccine recommendations set by the CDC's Advisory Committee on Immunization Practice.

A recent study from Brigham Young University introduced vaccine-hesitant students to survivors of the diseases that vaccines now can prevent.

The tropical-based virus is prevalent in areas inhabited by about one-third of the world's population.

Measles cases in the US have reached 700 this year, but the true threat is those who willingly exempt their children from the vaccination.

As providers, we do not want to scare parents into worrying about every cough or fever. Not every illness is sepsis.

Scientists at the Task Force for Global Health describe what is needed to eliminate HBV and HCV as public health threats.